Skip to main content

Month: May 2023

Power Electronics Market to Worth USD 153.30 Billion by 2030 | Fortune Business Insights™

Key companies covered in Power Electronics Market are Texas Instruments (U.S.), Infineon Technologies (Germany), On Semiconductor (U.S.), Analog Devices Inc. (U.S.), TDK (Japan), Qualcomm (U.S.), STMicroelectronics (Switzerland), Murata Manufacturing (Japan), Vishay Inter technology (U.S.), ROHM (Japan), and more players profiled. Pune, India, May 16, 2023 (GLOBE NEWSWIRE) — The global power electronics market size was valued at USD 52.70 billion in 2022 and is projected to grow from USD 61.94 billion in 2023 to USD 153.30 billion by 2030, recording a CAGR of 13.8% during the forecast timeframe of 2023-2030. The global market is estimated to grow at a notable pace as these devices are being extensively used in several sectors such as aerospace, automotive, defense, residential, healthcare, space, and industrial. Various power electronic...

Continue reading

Aircraft Aftermarket Parts Market Projected to Hit USD 47.33 Billion by 2028 | Fortune Business Insights™

The global aircraft aftermarket parts market covered major segments By Parts Type (MRO Parts and Routable Replacement Parts), By Component Type (Engine, Airframe, Interior, Cockpit Systems, and Others), By Aircraft (Narrow-body, Wide-body, and Regional Aircraft), and Region. Pune, India, May 16, 2023 (GLOBE NEWSWIRE) — The global aircraft aftermarket parts market size is expected to gain momentum by reaching USD 47.33 billion by 2028 while exhibiting a CAGR of 6.12% between 2021 and 2028. This information is published by Fortune Business Insights in its latest report, titled, “Aircraft Aftermarket Parts Market, 2021-2028.”  The report further mentions that the market stood at USD 29.44 billion in 2020. Factors such as the increasing number of phasing out of the aging aircraft and the estimated growth in air travel in near future...

Continue reading

FORVIA CONFIRMS THE SUCCESSFUL PROGRESS OF ITS ASSET DISPOSAL PROGRAM WITH THE ENTRY OF STELLANTIS IN SYMBIO’S CAPITAL

NANTERRE (FRANCE)MAY 16, 2023 FORVIA CONFIRMS THE SUCCESSFUL PROGRESS OF ITS ASSET DISPOSAL PROGRAM WITH THE ENTRY OF STELLANTIS IN SYMBIO’S CAPITAL With the acquisition by STELLANTIS of a stake in SYMBIO (a joint venture between Faurecia and MICHELIN), confirmed this morning in a joint press release by the three partners, Faurecia will receive a total amount of €150 million which will contribute to its €1 billion asset disposal program by the end of 2023. This asset disposal program includes two other operations already announced, representing together a cumulated enterprise value of almost €700 million:The sale of Faurecia’s SAS Cockpit Modules division (assembly and logistics services) to the Motherson Group, announced on February 19, is currently subject to regulatory approvals and the closing is expected early Q3 2023. The...

Continue reading

Stellantis to Acquire Equal Stake with Faurecia and Michelin in Symbio, a Leader in Zero-emission Hydrogen Mobility

Stellantis to Acquire Equal Stake with Faurecia and Michelin in Symbio, a Leader in Zero-emission Hydrogen Mobility AMSTERDAM, NANTERRE, PARIS, May 16, 2023 – Faurecia, a company of the FORVIA group, Michelin and Stellantis announce today the signing of a binding agreement for Stellantis to acquire 33.3% stake in Symbio, a leader in zero-emission hydrogen mobility. Faurecia and Michelin will remain shareholders with 33.3% holding each. The announcement is a significant step in the decarbonization of the mobility industry and illustrates Symbio’s technological excellence in hydrogen fuel cell innovations. The addition of Stellantis as a shareholder will boost Symbio’s development across Europe and in the U.S. “Acquiring an equal stake in Symbio will bolster our leadership position in hydrogen-powered vehicles by supporting our fuel...

Continue reading

Report for the three months ended 31 March 2023

HighlightsAll main components have been delivered and turbine installation work has commenced at the Karskruv project, which is set to increase the annual power generation from 800 GWh to 1,100 GWh from 2024 onwards Successfully established an organic growth platform across the Nordics and Europe, laying the foundation for growth in onshore wind, solar and battery storage solutions Further expanded the business in Finland with an experienced partner, adding a strong network and access to several exclusive brownfield and greenfield project opportunities Progressing several standalone and co-located projects in Sweden, with certain land rights already secured and ongoing work to secure grid connections and permits Expanded the European footprint to include the UK, Germany and France, and secured grid connections for solar and battery storage...

Continue reading

ONWARD Reports Q1 Business Update and Year-To-Date Highlights

First-in-Human Use of the ARC-IM™ Lead New Breakthrough Device Designation Awarded by the U.S. FDA for ARC Therapy™, Bringing Total to 9 10 Additional Patents Issued, Bringing Total Pending and Issued Patents to More than 340 and Strengthening First-Mover AdvantageEINDHOVEN, the Netherlands, May 16, 2023 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today provided a first quarter 2023 business update. “Our team continued to execute at a high level in Q1, achieving milestones and adding strength across our range of activities,” said Dave Marver, CEO of ONWARD. “We were especially pleased to announce that the Up-LIFT pivotal study met all primary endpoints...

Continue reading

Total number of voting rights and shares

(in accordance with the Law and Grand-ducal Regulation of 11 January 2008 on transparency requirements for issuers) Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached(including the issuer reference number allocated by the CSSF): SOLUTIONS 30 SE – identifiant E608 Identity of the notifier (if another person makes the notification on behalf of the issuer)– Total number of shares composing the share capital of the notifying issuer 107,127,984 Total number of voting rights attached to the shares composing the share capital of the notifying issuer, including the suspended voting rights107,127,984 Origin of the changeN.A. Date when the change occurredN.A. SOLUTIONS 30 SE3 rue de la Reine L-2418 LuxembourgR.C.S. Luxembourg: B 179.097www.solutions30.comAttachmentS30_VotingRights_Shares-AGM2022 ...

Continue reading

GOGL – First Quarter 2023 Results

Golden Ocean Group Limited (NASDAQ/OSE: GOGL) (the “Company” or “Golden Ocean”), the world’s largest listed owner of large size dry bulk vessels, today announced its unaudited results for the quarter ended March 31, 2023. HighlightsNet loss of $8.8 million and loss per share of $0.04 (basic) for the first quarter of 2023, including vessel impairment loss of $11.8 million relating to the sale of two older vessels. This compares with a net income of $68.2 million and earnings per share of $0.34 (basic) for the fourth quarter of 2022. Adjusted EBITDA of $54.7 million for the first quarter of 2023, compared with $112.4 million for the fourth quarter of 2022. Reported TCE rates for Capesize and Panamax/Ultramax vessels of $13,620 per day and $16,630 per day, respectively, and $14,929 per day for the entire fleet in the first quarter...

Continue reading

Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress

Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational ProgressHalle (Saale) / Munich, Germany, May 16, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced financial results and corporate updates for the first quarter of 2023, ending March 31, 2023. “In the first quarter of 2023, we continued to advance our lead program for Alzheimer’s disease, varoglutamstat, through both the VIVIAD and VIVA-MIND studies and reported further data demonstrating both strong tolerability and improvements in pathological hallmarks, synaptic function and connectivity, cognition, memory and attention in AD patients,”...

Continue reading

NORBIT – Results for the first quarter 2023

Trondheim, 16 May 2023: In the first quarter, NORBIT reached all-time high revenues of NOK 376.7 million, corresponding to a growth of 60 per cent from the first quarter of 2022, supported by strong demand in all three business segments. The EBITDA result was NOK 104.3 million in the first quarter, representing a margin of 28 per cent, up from NOK 43.9 million and 19 per cent in the corresponding quarter of 2022. Earnings per share for the quarter were NOK 0.88 compared to NOK 0.21 one year earlier. – The combination of continued strong demand and dedication across all levels of our organisation, has resulted in record high revenues and growth and further margin expansion. We are eager to continue to tailor technology that can enable our customers to «Explore More», says Per Jørgen Weisethaunet, CEO of NORBIT.    Order intake has...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.